Results 121 to 130 of about 28,303 (260)

Waist‐to‐height ratio and renal dysfunction as independent correlates of low handgrip strength in patients with type 2 diabetes

Journal of Diabetes Investigation, EarlyView.
In 1,468 patients with type 2 diabetes, central obesity (WHtR >0.5) neutralizes the protective effects of higher BMI on muscle strength. Concurrently, visceral adiposity and CKD impose an additive threat, maximizing low handgrip strength risk (aOR = 1.74). Combining WHtR and renal tracking optimizes clinical sarcopenia screening.
Shing‐Hua Chen, Chen‐Kai Chou, Shao‐Wen Weng, Jung‐Fu Chen, Feng‐Chih Shen   +4 more
wiley   +1 more source

Clinical characteristics of Sarcopenic obesity in Japanese people with type 2 diabetes: A post hoc analysis of the sub‐cohort iDIAMOND study

Journal of Diabetes Investigation, EarlyView.
Among participants aged 40–75 years, sarcopenic obesity was observed in 4.9% of those with T2D and 0.5% of non‐D individuals. Sarcopenic obesity is more prevalent in individuals with T2D and is associated with impaired physical QOL, reduced walking ability, and increased falls.
Hiroyasu Mori, Kasei Ko, Satoko Notomi, Sumiko Yoshida, Tetsuyuki Yasuda, Yutaka Umayahara, Sayoko Shimizu, Kayoko Ryomoto, Kazutomi Yoshiuchi, Saeko Osawa, Tsunehiko Yamamoto, Akio Kuroda, Munehide Matsuhisa   +12 more
wiley   +1 more source

USP30 inhibits wound healing in diabetic foot ulcers by promoting TRAF6‐induced ferroptosis and angiogenesis inhibition

Journal of Diabetes Investigation, EarlyView.
High glucose upregulates USP30 in HUVECs, which deubiquitinates and stabilizes TRAF6. Stabilized TRAF6 suppresses GPX4 and SLC7A11, increases ROS/MDA/lipid peroxidation, and activates ferroptosis and apoptosis, leading to impaired angiogenesis and delayed wound healing.
Jingjing Yuan, Shuang Sui, Zhenghua Yang, Kaiwen Zhang, Qiang Hu   +4 more
wiley   +1 more source

Caution in handling switchers in pharmacoepidemiologic studies estimating treatment effects: the example of dipeptidyl peptidase-4 inhibitors and inflammatory bowel disease. [PDF]

Am J Epidemiol
Wang T, Wang J, Song Z, Miller E, Pate V, Her Q, Yang J, Charlier SHR, Egger P, Barnes EL, Buse JB, Becker C, Sandler RS, Meier C, Jick S, Stürmer T.   +15 more
europepmc   +1 more source

Cardiovascular preventive role of thiazolidinedione in patients with type 2 diabetes mellitus undergoing percutaneous coronary intervention

Journal of Diabetes Investigation, EarlyView.
Among patients with type 2 diabetes undergoing percutaneous coronary intervention, thiazolidinedione use was independently associated with a significantly reduced risk of a composite of myocardial infarction, stroke, and all‐cause death, notably without an increased risk of admission for heart failure. ABSTRACT Background Thiazolidinediones (TZD) are a
Jinkwon Kim, Jimin Jeon, Joonsang Yoo, Minyoul Baik, Seok‐Jae Heo, Ji Woong Roh   +5 more
wiley   +1 more source

Phenotype-Specific Mortality Outcomes with Dipeptidyl Peptidase-4 Inhibitors in Heart Failure and Diabetes: Real-World Evidence from a Retrospective Single-Center Cohort Study. [PDF]

J Clin Med
Alfehaid L, Alamer A, Alhantush A, Yami MSA.   +3 more
europepmc   +1 more source

Sodium zirconium cyclosilicate compared with potassium restriction for hyperkalemia management in type 2 diabetes: The SILVERSTAR trial

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims/Introduction To demonstrate noninferiority of continued sodium zirconium cyclosilicate therapy versus a potassium‐restricted diet in achieving normokalemia at Visit 7 (Days 28–42) in individuals with type 2 diabetes and hyperkalemia, using a noninferiority margin of −10 percentage points (one‐sided α = 0.025).
Masahide Hamaguchi, Junya Hironaka, Hiroshi Okada, Mari Yoneda, Ayaka Kobayashi, Yoshitaka Hashimoto, Aya Kitae, Noriyuki Kitagawa, Akio Kishi, Michiyo Ishii, Mai Asano, Masahiro Yamazaki, Toru Tanaka, Hanako Nakajima, Eiko Sato, Michiaki Fukui   +15 more
wiley   +1 more source

Analysing the Shift in Prescribing Patterns: Sodium Glucose Co-transporter 2 Inhibitors, Dipeptidyl Peptidase 4 Inhibitors and Traditional Antidiabetic Drugs

Online Journal of Health & Allied Sciences
India currently has around 77 million adults living with diabetes. Considering the growing impact of diabetes-related complications, we aimed to compare the real-world prescribing patterns of sodium-glucose cotransporter-2 inhibitors, dipeptidyl ...
Vini Pavithran, Pandiyan Balachandran, Chadappully Ismail Sajeeth, Athiappan Hariharan   +3 more
doaj  

Insulin‐reducing effect of adding imeglimin to ongoing dipeptidyl peptidase‐4 inhibitor therapy with multiple daily insulin injections (INSPIRE study)

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Introduction Simplifying multiple daily insulin injections (MDI) has attracted great interest in clinical practice. Although imeglimin shows good compatibility with dipeptidyl peptidase‐4 inhibitors (DPP‐4i), its effectiveness in patients treated with MDI remains unclear.
Atsushi Itsukaichi, Fukumi Yoshikawa, Manabu Saito, Ayako Fuchigami, Yoko Iwata, Genki Sato, Hiroshi Uchino, Takahisa Hirose   +7 more
wiley   +1 more source

The miR‐145‐5p/NRF2/SLC7A11 axis regulates ferroptosis‐mediated renal tubular epithelial cell injury in diabetic nephropathy

Journal of Diabetes Investigation, EarlyView.
Suppression of miR‐145‐5p alleviates DN‐associated renal tissue damage by inhibiting NRF2/SLC7A11‐mediated ferroptosis of RTECs. ABSTRACT Purpose This study aimed to investigate the molecular mechanism by which the miR‐145‐5p/NRF2/SLC7A11 axis regulates ferroptosis‐mediated renal tubular epithelial cell (RTEC) injury in diabetic nephropathy (DN ...
Ganlin Wu, Yu Fang, Meirong Xu, Zuopeng Lu, Yu Cao, Yana Gao   +5 more
wiley   +1 more source